Hyperfine (NASDAQ:HYPR – Get Free Report) and Avanos Medical (NYSE:AVNS – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
Valuation & Earnings
This table compares Hyperfine and Avanos Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hyperfine | $19.06 million | 3.05 | -$35.57 million | ($0.30) | -1.82 |
| Avanos Medical | $715.90 million | 1.64 | -$72.90 million | ($1.61) | -15.52 |
Hyperfine has higher earnings, but lower revenue than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Hyperfine has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Hyperfine and Avanos Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hyperfine | 1 | 1 | 3 | 1 | 2.67 |
| Avanos Medical | 1 | 1 | 0 | 0 | 1.50 |
Hyperfine presently has a consensus price target of $1.98, suggesting a potential upside of 261.39%. Given Hyperfine’s stronger consensus rating and higher probable upside, equities analysts clearly believe Hyperfine is more favorable than Avanos Medical.
Insider & Institutional Ownership
15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 95.2% of Avanos Medical shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by insiders. Comparatively, 2.3% of Avanos Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Hyperfine and Avanos Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hyperfine | -156.42% | -91.18% | -55.49% |
| Avanos Medical | -10.39% | 5.39% | 3.97% |
Summary
Hyperfine beats Avanos Medical on 9 of the 15 factors compared between the two stocks.
About Hyperfine
Hyperfine, Inc. develops portable magnetic resonance imaging (MRI) technology for brain imaging. Its Swoop system is a low-field MRI scanner designed to bring imaging to patients at the point of care, including settings where access to conventional MRI equipment may be limited. The Swoop system is designed for use near a patient’s bedside and does not require a dedicated MRI suite. The U.S. Food and Drug Administration cleared the system in 2020, marking a milestone for the use of portable MRI in clinical care.
About Avanos Medical
Avanos Medical, Inc. develops and markets medical devices and related products, with a focus on digestive health and pain management. Its offerings include enteral feeding tubes and delivery systems, as well as devices used in regional anesthesia and non-opioid pain management. The company’s products are used in hospitals, other health care facilities and home-care settings. Avanos serves customers in the United States and internationally. Avanos traces its history to Halyard Health, which became an independent company after separating from Kimberly-Clark in 2014.
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
